BioSpace News Archive

Vaxart, Inc. urges its stockholders of record on April 11, 2022, to vote on its proxy if they have not yet done so.

The Leukemia & Lymphoma Society announced National Board Officer appointments, as well as a new national board member.

IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter™ single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy.

AstraZeneca presented data for IMFINZI® (durvalumab) combinations from the HIMALAYA and TOPAZ-1 Phase III trials at the European Association for the Study of the Liver’s International Liver Congress 2022 (EASL 2022) and the European Society for Medical Oncology’s World Congress on Gastrointestinal Cancer (ESMO World GI 2022).

Recent Publications By Kuick Research Highlights Emergence Of Antibodies As Fundamental Premise For The Growth Of Targeted Cancer Drug Market Market.

Their critical role in development and –progression of cancer has led to introduction of MEK inhibitors as potential approach in cancer management.

Transdermal Patch Drug Deliver Market Opportunity To Surpass USD 20 Billion By 2028 As Per Kuick Research Report Findings.

Rare cancers or orphan cancers are group of cancer which generally affect so few people that drug development for such diseases is considered unprofitable and neglected by the pharmaceutical companies.

Agile Therapeutics, Inc. announced the pricing of its upsized public offering of an aggregate of 26,666,666 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $0.90 per share and accompanying warrants.

Orphan Designated Drugs For Rare Cancers Accounts For More Than 40% Of Global Orphan Drug Sales As Per Kuick Research Report.